Market Research Logo

Global Resipiratory Drugs Market 2016-2020

About Respiratory Ailments

Asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and IPF are some of the major respiratory diseases. Among these, asthma and COPD are the most prevalent worldwide. Environmental pollution, changing lifestyles, and hereditary factors are some of the common causes of respiratory diseases. Intranasal corticosteroids, antihistamines, immunosuppressants, bronchodilators, and leukotriene antagonists are the respiratory medicines that are commonly used for the treatment of mild-to-moderate respiratory diseases. However, the choice of drug depends on the type and severity of the disease.

Technavio’s analysts forecast the global respiratory drugs market to grow at a CAGR of 6.48% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global respiratory drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription and over-the-counter (OTC) drugs used to treat respiratory diseases.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Respiratory Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Boehringer Ingelheim
  • F.Hoffman La-Roche
  • GlaxoSmithKline
  • Merck
  • Novartis
Other prominent vendors
  • Abbott
  • Actavis
  • Afferent Pharmaceuticals
  • Alere
  • Almirall
  • Amgen
  • AptarGroup
  • Astellas
  • Aurobindo
  • Axis Shield
  • Baxter
  • Bayer
  • Biogen
  • Biotest
  • Bristol-Myers Squibb
  • Chiesi Farmaceutici
  • Cipla
  • Cytos
  • Dainippon Sumitomo
  • Dr. Reddy's Laboratories
  • FibroGen
  • Gilead Sciences
  • Glenmark
  • GNI Group Ltd
  • Horizon Pharma
  • ImmuneWorks
  • MediciNova
  • MedImmune
  • Mylan
  • Ono Pharmaceutical
  • Orchid Chemicals and Pharmaceuticals
  • Perrigo
  • Pfizer
  • Promedior
  • Prometheus
  • ProMetic Life Sciences
  • Ranbaxy
  • Rottapharm Madaus
  • Sanofi
  • Shionogi
  • Siemens Healthcare Diagnostics
  • Skyepharma
  • Sosei


  • Sunovion
  • Takeda Pharmaceutical
  • Teva
  • Theravance
  • United Therapeutics
  • Vectura
  • Vertex
  • Zai Lab
Market driver
  • Rise in prevalence of respiratory diseases
  • For a full, detailed list, view our report
Market challenge
  • Unknown etiology of asthma and idiopathic pulmonary fibrosis
  • For a full, detailed list, view our report
Market trend
  • Use of biologics
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Respiratory Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global respiratory drugs market: AstraZeneca, Boehringer Ingelheim, F.Hoffman-La Roche, GlaxoSmithKline, Merck, and Novartis.

Other Prominent Vendors in the market are: Abbott, Actavis, Afferent Pharmaceuticals, Alere, Almirall, Amgen, AptarGroup, Astellas, Aurobindo, Axis Shield, Baxter, Bayer, Biogen, Biotest, Bristol-Myers Squibb, Chiesi Farmaceutici, Cipla, Cytos, Dainippon Sumitomo, Dr. Reddy's Laboratories, FibroGen, Gilead Sciences, Glenmark, GNI Group Ltd, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune, Mylan, Ono Pharmaceutical, Orchid Chemicals and Pharmaceuticals, Perrigo, Pfizer, Promedior, Prometheus, ProMetic Life Sciences, Ranbaxy, Rottapharm Madaus, Sanofi, Shionogi, Siemens Healthcare Diagnostics, Skyepharma, Sosei, Sunovion, Takeda Pharmaceutical , Teva, Theravance, United Therapeutics, Vectura, Vertex, and Zai Lab.

Commenting on the report, an analyst from Technavio’s team said: “A noteworthy trend in the respiratory drugs market is the use of biologics. In recent times, biologics are increasingly becoming the preferred choice to treat respiratory diseases, and they act by blocking the interleukins and reducing inflammation caused in the respiratory tract. For example, Xolair (omalizumab) by Genentech and Novartis is the only approved biologic drug for the treatment of asthma.”

According to the report, a key growth driver is the rising prevalence of respiratory diseases around the world. The CDC reported that as of May 2011, about 25 million Americans, which isone in 12 individuals in the US, had asthma. In 2015, the National Institute of Allergy and Infectious Diseases (NIAID) reported that globally about 250 million people had asthma. According to the WHO factsheet 2016, approximately 8% of the Swiss population, four million Germans, three million Japanese, and 15-20 million Indians are estimated to have asthma. Many respiratory occur due to genetic factors and lifestyle factors such as vehicular pollution and exposure to animals or pets. Rising prevalence of respiratory diseases results in more people seeking treatment, increasing the intake of medicines, thereby contributing to the respiratory drugs market.

Further, the report states that a major challenge with the potential to hamper market growth is the unknown etiology of respiratory problems like asthma and idiopathic pulmonary fibrosis.

Companies Mentioned

AstraZeneca, Boehringer Ingelheim, F.Hoffman-La Roche, GlaxoSmithKline, Merck, Novartis, Abbott, Actavis, Afferent Pharmaceuticals, Alere, Almirall, Amgen, AptarGroup, Astellas, Aurobindo, Axis Shield, Baxter, Bayer, Biogen, Biotest, Bristol-Myers Squibb, Chiesi Farmaceutici, Cipla, Cytos, Dainippon Sumitomo, Dr. Reddy's Laboratories, FibroGen, Gilead Sciences, Glenmark, GNI Group Ltd, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune, Mylan, Ono Pharmaceutical, Orchid Chemicals and Pharmaceuticals, Perrigo, Pfizer, Promedior, Prometheus, ProMetic Life Sciences, Ranbaxy, Rottapharm Madaus, Sanofi, Shionogi, Siemens Healthcare Diagnostics, Skyepharma, Sosei, Sunovion, Takeda Pharmaceutical , Teva, Theravance, United Therapeutics, Vectura, Vertex, Zai Lab.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Overview: Respiratory diseases
    • Asthma
      • Table Objectives of asthma management
    • COPD
      • Table COPD: Prevalence in six EU countries
      • Table Management of COPD
    • Allergic rhinitis
      • Table Prevalence rate of allergic rhinitis in China
      • Table Summary of pharmacologic treatments for allergic rhinitis
      • Table Non-pharmacological therapies for allergic rhinitis
    • Pulmonary hypertension
    • Cystic fibrosis
      • Table Prevalence of cystic fibrosis by country 2014
    • IPF
      • Table Treatment options for IPF
    • US FDA-approved respiratory drugs
      • Table Drugs approved by US FDA for respiratory diseases 2000-2015
  • Pipeline analysis
    • Table Pipeline portfolio of major drug candidates for respiratory diseases
    • Information on some pipeline candidates
  • Market landscape
    • Table Global respiratory drugs market 2015-2020 ($ billions)
    • Table Global respiratory drugs market by diseases 2015
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by class of drugs
    • Bronchodilators
    • Leukotriene antagonists
    • Mast cell stabilizers
    • Immunosuppressants
    • Combination of LABA/ICS
    • Tyrosine kinase inhibitors
    • Antifibrotic agents
    • Antihistamines
    • Endothelin (ET) receptor antagonist
    • Prostacyclin analogs
    • Phosphodiesterase inhibitors
    • Soluble guanylate cyclase (sGC) stimulators
  • Market segmentation by disease
    • Global asthma drugs market
      • Table Global asthma drugs market 2015-2020 ($ billions)
      • Table Key drivers and challenges of global asthma drugs market
      • Table Global asthma drugs market by class of drugs 2015
    • Global COPD drugs market
      • Table Global COPD drugs market 2015-2020 ($ billions)
      • Table Key drivers and challenges of global COPD drugs market
      • Table Global COPD drugs market by class of drugs 2015
    • Global allergic rhinitis drugs market
      • Table Global allergic rhinitis drugs market 2015-2020 ($ billions)
      • Table Key drivers and challenges of global allergic rhinitis drugs market
      • Table Global allergic rhinitis drugs market by class of drugs 2015
    • Global pulmonary hypertension drugs market
      • Table Global pulmonary hypertension drugs market 2015-2020 ($ billions)
      • Table Key drivers and challenges for global pulmonary hypertension drugs market
      • Table Global pulmonary hypertension drugs market by class of drugs 2015
    • Global cystic fibrosis drugs market
      • Table Global cystic fibrosis drugs market 2015-2020 ($ billions)
      • Table Key drivers and challenges for global cystic fibrosis drugs market
      • Table Global cystic fibrosis drugs market by type of molecule 2015
    • Global IPF drugs market
      • Table Global IPF market 2015-2020 ($ billions)
      • Table Key drivers and challenges for global IPF drugs market
      • Table Global respiratory drugs market: YoY revenue and growth based on respiratory diseases 2015-2020
  • Geographical segmentation
    • Global respiratory drugs market by geography 2015-2020
      • Table Global respiratory drugs market by geography 2015
      • Table Global respiratory drugs market revenue by geography 2015-2020 ($ billions)
    • Respiratory drugs market in Americas
      • Table Respiratory drugs market in Americas 2015-2020 ($ billions)
    • Respiratory drugs market in EMEA
      • Table Respiratory drugs market in EMEA 2015-2020 ($ billions)
    • Respiratory drugs market in APAC
      • Table Respiratory drugs market in APAC 2015-2020 ($ billions)
      • Table Global respiratory drugs market; YoY revenue and growth based on geography 2015-2020
  • Market drivers
    • Promising late-stage pipeline molecules
    • Rise in prevalence of respiratory diseases
    • Increase in older adult population
    • High usage of tobacco
    • Increase in environmental pollution
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Multiple patent expiries
    • Unknown etiology of asthma and IPF
    • Low diagnosis rates
    • Adverse effects of drugs
    • Increased preference for CAM
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increasing awareness about respiratory diseases
    • Patient assistance programs
    • Usage of biologics
    • Self-medication using OTC products
      • Table Drugs that converted from Rx to OTC
    • Strategic alliances
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Global respiratory drugs market share analysis 2015
      • Table Top selling respiratory drugs based on their revenue in 2014
    • AstraZeneca
      • Table AstraZeneca: Percentage share of products sales by therapy area 2014
      • Table AstraZeneca: YoY growth and revenue of Symbicort 2012-2014 ($ billions)
      • Table AstraZeneca: YoY growth and revenue of Pulmicort 2012-2014 ($ billions)
      • Table AstraZeneca: Key takeaways
    • Boehringer Ingelheim
      • Table Boehringer Ingelheim: YoY growth and revenue of Spiriva 2012-2014 ($ billions)
      • Table Boehringer Ingelheim: YoY growth and revenue of Combivent 2012-2014 ($ millions)
      • Table Boehringer Ingelheim: Key takeaways
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: YoY growth and revenue of Xolair in the US 2012-2014 ($ millions)
      • Table F. Hoffmann-La Roche: YoY growth and revenue of Pulmozyme 2012-2014 ($ millions)
      • Table F. Hoffmann-La Roche: Key takeaways
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Percentage share of products sales by therapy area 2014
      • Table GlaxoSmithKline: YoY growth and revenue of Seretide/Advair 2012-2014 ($ billions)
      • Table GlaxoSmithKline: YoY growth and revenue of Flixotide/Flovent 2012-2014 ($ billions)
      • Table GlaxoSmithKline: YoY growth and revenue of Ventolin 2012-2014 ($ billions)
      • Table GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
      • Table GlaxoSmithKline: YoY revenue of Avamys/Veramyst 2013 and 2014 ($ millions)
      • Table GlaxoSmithKline: Key takeaways
    • Merck
      • Table Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)
      • Table Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)
      • Table Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)
      • Table Merck: Key takeaways
    • Novartis
      • Table Novartis: YoY growth and revenue of Xolair (outside the US) 2012-2014 ($ millions)
      • Table Novartis: YoY growth and revenue of TOBI 2012-2014 ($ millions)
      • Table Novartis: YoY growth and revenue of Onbrez Breezhaler 2012-2014 ($ millions)
      • Table Novartis: YoY growth and revenue of Seebri Breezhaler 2012-2014 ($ millions)
      • Table Novartis: YoY revenue of Ultibro Breezhaler 2013 and 2014 ($ millions)
      • Table Novartis: YoY growth and revenue of Foradil Aerolizer sold outside the US 2012- 2014 ($ millions)
      • Table Novartis: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report